Literature DB >> 33583413

Survival and biomarker analysis for ovarian mucinous carcinoma according to invasive patterns: retrospective analysis and review literature.

Taira Hada1, Morikazu Miyamoto2, Hiroki Ishibashi1, Hiroko Matsuura1, Takahiro Sakamoto1, Soichiro Kakimoto1, Hideki Iwahashi1, Hitoshi Tsuda3, Masashi Takano1.   

Abstract

BACKGROUND: In ovarian mucinous carcinoma, invasive pattern is the important factor but there were less reposts to investigate it. The aim of this study was to examine the association between prognosis and invasive patterns of ovarian mucinous carcinoma and to investigate the biomarkers of the diagnosis and prognosis immunochemically. Patients with ovarian mucinous carcinoma at our institution between 1984 and 2018 were identified. A pathological review was conducted using the 2020 World Health Organization criteria. The prognosis of infiltrative invasion and expansile invasion of ovarian mucinous carcinoma were retrospectively compared. In addition, immunohistochemical staining was conducted for all cases, and the immunohistochemical differences between the two invasive patterns were compared.
RESULTS: After the pathological review, 25 cases with infiltrative invasion and 24 cases with expansile invasion were included. Ovarian mucinous carcinoma with infiltrative invasion showed significantly worse progression-free survival (PFS, p < 0.01) and overall survival (OS, p < 0.01) than those with expansile invasion. Multivariate analysis demonstrated that the pattern of infiltrative invasion was a worse prognostic factor for PFS (hazard ratio 9.01, p < 0.01) and OS (hazard ratio 17.56, p < 0.01). Immunohistochemically, cytokeratin (CK) 5/6 (p = 0.01), cluster of differentiation (CD) 24 (p = 0.02), and epithelial growth factor receptor (EGFR) (p < 0.01) were statistically related to infiltrative invasion. The PFS (p = 0.04) and OS (p = 0.02) of cases with EGFR-positive OMC were worse than those with negative OMC.
CONCLUSIONS: Infiltrative invasion was observed to be a prognostic factor showing worse outcomes for ovarian mucinous carcinoma compared to expansile infiltration. CK5/6, CD24, and EGFR might be biomarkers of the diagnosis.

Entities:  

Keywords:  2020 World Health Organization; Expansile invasion; Infiltrative invasion; Invasive pattern; Ovarian mucinous carcinoma; Prognosis

Year:  2021        PMID: 33583413      PMCID: PMC7883414          DOI: 10.1186/s13048-021-00783-3

Source DB:  PubMed          Journal:  J Ovarian Res        ISSN: 1757-2215            Impact factor:   4.234


  37 in total

1.  HER2-positive mucinous adenocarcinomas of the ovary have an expansile invasive pattern associated with a favorable prognosis.

Authors:  Sang Kyum Kim; Nam Hoon Cho
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

Review 2.  Pathology of borderline and invasive cancers.

Authors:  Jaime Prat
Journal:  Best Pract Res Clin Obstet Gynaecol       Date:  2016-10-03       Impact factor: 5.237

3.  Expression of cytokeratin 5/6 in epithelial neoplasms: an immunohistochemical study of 509 cases.

Authors:  Peiguo G Chu; Lawrence M Weiss
Journal:  Mod Pathol       Date:  2002-01       Impact factor: 7.842

4.  CD24+ cells from hierarchically organized ovarian cancer are enriched in cancer stem cells.

Authors:  M-Q Gao; Y-P Choi; S Kang; J H Youn; N-H Cho
Journal:  Oncogene       Date:  2010-03-01       Impact factor: 9.867

5.  What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?

Authors:  D S Chi; E L Eisenhauer; J Lang; J Huh; L Haddad; N R Abu-Rustum; Y Sonoda; D A Levine; M Hensley; R R Barakat
Journal:  Gynecol Oncol       Date:  2006-05-22       Impact factor: 5.482

6.  Distinction of primary and metastatic mucinous tumors involving the ovary: analysis of size and laterality data by primary site with reevaluation of an algorithm for tumor classification.

Authors:  Anna V Yemelyanova; Russell Vang; Kara Judson; Lee-Shu-Fune Wu; Brigitte M Ronnett
Journal:  Am J Surg Pathol       Date:  2008-01       Impact factor: 6.394

7.  Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm.

Authors:  Dennis S Chi; Eric L Eisenhauer; Oliver Zivanovic; Yukio Sonoda; Nadeem R Abu-Rustum; Douglas A Levine; Matthew W Guile; Robert E Bristow; Carol Aghajanian; Richard R Barakat
Journal:  Gynecol Oncol       Date:  2009-04-23       Impact factor: 5.482

Review 8.  Mucinous epithelial ovarian carcinoma.

Authors:  T J Perren
Journal:  Ann Oncol       Date:  2016-04       Impact factor: 32.976

9.  Primary and metastatic mucinous adenocarcinomas in the ovaries: incidence in routine practice with a new approach to improve intraoperative diagnosis.

Authors:  Jeffrey D Seidman; Robert J Kurman; Brigitte M Ronnett
Journal:  Am J Surg Pathol       Date:  2003-07       Impact factor: 6.394

Review 10.  Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results.

Authors:  S M Huang; P M Harari
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.651

View more
  2 in total

1.  Prognostic similarity between ovarian mucinous carcinoma with expansile invasion and ovarian mucinous borderline tumor: A retrospective analysis.

Authors:  Taira Hada; Morikazu Miyamoto; Hiroki Ishibashi; Hiroko Matsuura; Takahiro Sakamoto; Soichiro Kakimoto; Hideki Iwahashi; Rie Suzuki; Kimiya Sato; Hitoshi Tsuda; Masashi Takano
Journal:  Medicine (Baltimore)       Date:  2021-08-13       Impact factor: 1.817

2.  Comparison of clinical behavior between mucinous ovarian carcinoma with infiltrative and expansile invasion and high-grade serous ovarian carcinoma: a retrospective analysis.

Authors:  Taira Hada; Morikazu Miyamoto; Hiroki Ishibashi; Hiroko Matsuura; Soichiro Kakimoto; Hideki Iwahashi; Hitoshi Tsuda; Masashi Takano
Journal:  Diagn Pathol       Date:  2022-01-20       Impact factor: 2.644

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.